Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Data Gathering for A10900

NCT07149740 · tracked via the Priya Life Science USA tracker
Sponsor
Optos, PLC
Phase
Observational
Started
2025-06-26
Last updated
2026-02-13

Condition(s) studied

Retinal DiseaseHealthyGlaucomaCorneal Diseases

Investigational drug(s) / intervention(s)

OCT

OCT: A10900 is an optical coherence tomography device

Study summary

The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
Accepted
Inclusion/Exclusion Criteria Inclusion Criteria for Retinal Disease Group 1. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. BCVA 20/400 or better in the study eye 4. Participants presenting at the site with retinal disease 5. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others Exclusion Criteria for Retinal Disease Group 1. Participants unable to tolerate ophthalmic imaging 2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons 3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study 4. Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and/or investigator assessment at the study visit; Inclusion Criteria for Glaucoma Group 1. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. BCVA 20/40 or better in the study eye 4. History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings: 1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; 2. Glaucoma hemi-field test "outside normal limits." 5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities: 1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage; 2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue Exclusion Criteria for Glaucoma Group 1. Participants unable to tolerate ophthalmic imaging 2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons 3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study 4. No reliable visual field test result within the previous year from the study visit, defined as fixation losses \> 33% or false positives \> 33%, or false negatives \> 33% in the study eye 5. Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group 1\. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures. Exclusion Criteria for Corneal Group 1. Participants unable to tolerate ophthalmic imaging 2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study 3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images. Inclusion Criteria for Normal Group 1. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed). 4. BCVA 20/40 or better (each eye) 5. Participant is able to comply with the study procedures Exclusion Criteria for Normal Group 1. Participants unable to tolerate ophthalmic imaging 2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study 3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images 4. History of leukemia, dementia or multiple sclerosis

Primary outcome measure(s)

  • Number of OCT Scans — 1 year

Trial sites (4)

FacilityCityRegionStatus
Ketchum Health Anaheim California Recruiting
Eye Disease Consultants, LLC West Hartford Connecticut Recruiting
Eye Care and Laser Surgery of Newton Wellselley Wellesley Hills Massachusetts Completed
Charles Retina Institute Germantown Tennessee Recruiting

More Optos, PLC trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07149740 on ClinicalTrials.gov ↗ ← All trials in the USA